Abstract

Breast cancer is a biologically heterogeneous disease whose clinical outcomes are shaped by complex interactions 
among tumor cells, immune components, and the surrounding microenvironment. Recent advances in single-cell 
and spatial omics technologies have enabled unprecedented resolution in the characterization of tumor ecosystems, 
allowing researchers to analyze cellular phenotypes, transcriptional programs, protein expression, and spatial 
organization simultaneously. This paper reviews the role of single-cell and spatial omics in breast cancer 
stratification, emphasizing translational pathways from biomarker discovery to diagnostic, prognostic, and 
therapeutic applications. It examines how multi-omics integration supports the identification of tumor intrinsic 
subtypes, cellular ecosystems, and predictive biomarkers for therapy selection and resistance monitoring. The 
review further explores requirements for analytical and clinical validation, prospective trials, and real-world data 
integration necessary for population-level implementation. Key adoption barriers, including technical complexity, 
infrastructure demands, economic constraints, workforce limitations, and ethical and governance considerations, 
are critically discussed alongside emerging facilitators such as artificial intelligence, standardized data frameworks, 
and collaborative translational programs. The paper concludes that while single-cell and spatial omics hold 
transformative potential for precision oncology and population-scale breast cancer management, coordinated 
efforts in validation, standardization, policy development, and equitable resource allocation are essential to enable 
responsible clinical adoption and maximize public-health impact.